



## **Luminous Mind, Inc. Welcomes Raymond C. Kubacki to its Board of Directors**

Boston, MA - May 7, 2024 - Luminous Mind, Inc. (LMI), a pioneering [biopharmaceutical company](#) dedicated to revolutionizing the treatment landscape for neuropsychiatric disorders, proudly announces the appointment of [Raymond C. Kubacki](#) to its board of directors.

With over three decades of executive leadership and a proven track record of success, Raymond C. Kubacki brings invaluable expertise to LMI's board. His extensive experience in corporate governance, regulatory affairs and strategic planning will play a pivotal role in guiding Luminous Mind's mission to develop transformative therapies for patients suffering from anxiety, depression, chronic pain, PTSD, anorexia, and schizophrenia.

Louis Herlands, Ph.D., Chairman and CEO of Luminous Mind, expressed his excitement about Kubacki's appointment, stating, "Ray's wealth of knowledge and corporate leadership experience will be instrumental as we advance our innovative pipeline of CNS treatments. His strategic insights and deep understanding of regulatory processes will enhance our ability to bring novel therapies to patients in need."



Prior to joining LMI's board, Raymond C. Kubacki has served as Chairman of the Board, President, and CEO of Psychomedics Corporation (PMD:NASDAQ), where he led the company to achieve significant milestones in drug testing and regulatory clearances. He successfully guided PMD through the US FDA clearance process and the US and Foreign Patent process numerous times.

His experience in corporate governance and board excellence has been recognized by the American College of Corporate Directors when they honored Mr. Kubacki with their "Distinguished Director Award" in 2019. He received his B.A. from Harvard College and his M.B.A from Harvard Business School.

Commenting on his new role, Kubacki stated, "I am honored to join Luminous Mind's board of directors and contribute to the company's groundbreaking work in CNS therapeutics. Together with Louis and the rest of the Luminous Mind team, I look forward to driving innovation and making a meaningful impact on the lives of patients worldwide."

### **About Luminous Mind, Inc.:**

Luminous Mind Inc., with its focus on Central Nervous System (CNS) disorders, applies a rigorous therapeutic discovery and development process that includes the repurposing of existing, abandoned, and developmental compounds for new indications. Groundbreaking scientific insights in neuroscience, genetics, systems biology, and brain circuitry, together with powerful new tools drive its discovery efforts. For additional information, please visit [www.LuminousMindInc.com](http://www.LuminousMindInc.com).

### **Contact:**

Louis Herlands, Ph.D.  
Chairman and CEO  
Email: [LHerlands@LuminousMindInc.com](mailto:LHerlands@LuminousMindInc.com)  
Phone: 800-816-9630 ext. 702  
Location: Cambridge, MA